Focus

Biotech Investors: Angels and VC Firms

The RaiseHunt database lists 15,303 Biotech investors: 2,501 angel investors and 12,802 people at 3,692 firms. Most list Seed and Series A among their stages; the largest hubs are New York, San Francisco and London.

Strongest in New York, San Francisco and London

Common stages: Seed and Series A

15,303
Biotech investors
2,501
Angel investors
12,802
People at VC/PE firms
3,692
Firms tagged

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

15,303 Biotech investors

Showing 1-20

Filters
Mountain View, United States
AngelOperator angel
AIHardware
View profile
Matt McIlwain
Matt McIlwain

Managing Director

Seattle, United States
Angel
AIHealthcare
View profile
Amanda Wooding
Amanda Wooding

Investment Director

Cambridge, United Kingdom
Angel
AIHardware
View profile
San Francisco, United States
AngelOperator angel
AIConsumer
View profile
Marina Hadjipateras
Marina Hadjipateras

Founder and Managing Partner

New York, United States
Angel
AICommerce
View profile
New York, United States
AngelOperator angel
ConsumerFinTech
View profile
Chicago, United States
AngelOperator angel
Healthcare
View profile
Ross Youngs
Ross Youngs

CEO & Co-Founder

Dublin, United States
AngelOperator angel
ClimateHealthcare
View profile
Liz Keen
Liz Keen

Chief Strategy Officer

United States
AngelOperator angel
ClimateHardware
View profile
San Mateo, United States
AngelOperator angel
AIHardware
View profile
Stephan Apel
Stephan Apel

Founding Partner & Board Member

United Kingdom
AngelOperator angel
AIFinTech
View profile
Benoist Grossmann
Benoist Grossmann

CEO Eurazeo Investment Manager

Paris, France
Angel
AIConsumer
View profile
Sebastien Breteau
Sebastien Breteau

Founder & CEO

United Kingdom
AngelOperator angel
ClimateEducation
View profile
San Francisco, United States
Angel
AIFinTech
View profile
United States
AngelOperator angel
CommerceConsumer
View profile
Sami Inkinen
Sami Inkinen

Venture Partner

Denver, United States
AngelOperator angel
AIHardware
View profile
William Hines
William Hines

Chapter Head Distribution and Tender Management

Dubai, United Arab Emirates
AngelOperator angel
AgricultureFood
View profile
New York, United States
AngelOperator angel
AIFinTech
View profile
Gina Bianchini
Gina Bianchini

Member Board of Directors

Palo Alto, United States
AngelOperator angel
ConsumerEducation
View profile
New York, United States
Angel
AIEnergy
View profile

900 of 15,303 Biotech investors, A to Z

Grouped by first letter. Name and profile link only, the detailed rows are in the table above.
Show

A93

B43

C48

D46

E45

F15

G28

H16

I9

J122

K45

L32

M80

N26

O9

P26

Q1

R53

S89

T35

U2

V12

W11

X1

Y5

Z8

Frequently asked questions

How many Biotech investors are on RaiseHunt?

RaiseHunt currently lists 15,303 Biotech investors.

Are Biotech investors angels or funds?

Both. 2,501 are angel investors putting in their own money, and 12,802 are people making investment decisions at 3,692 firms.

Where are most Biotech investors based?

The largest concentrations are in New York, San Francisco and London.

What stage do Biotech investors invest at?

Most list Seed and Series A among the rounds they take part in.

How do I contact Biotech investors?

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Is the list of Biotech investors free to browse?

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

Do Biotech investors only back Biotech companies?

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

How many Biotech investors should I contact?

Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a list of a handful of perfect names tends to stall. Build a long list, sort it by how well each one matches what you are building, and work down it in batches rather than sending everything at once.

What should I have ready before reaching out?

A short deck, a one-paragraph description of what you do and who it is for, and a clear number for how much you are raising. Investors read the first two lines before they decide whether to open the deck, so those lines matter more than the rest of the document.

Does a warm introduction still matter?

It helps, mostly because it moves your email out of a crowded inbox. It is not a requirement. A cold message that shows you understand what someone has already backed, and why your company fits that pattern, gets read more often than a vague introduction from a distant contact.

How do I know which Biotech investors are a fit?

Look at what they have already funded rather than what their profile says they like. Stage matters most, then sector, then geography. An investor who has never funded anything at your stage is unlikely to start with you, however well the sector lines up.

How long does raising a round usually take?

Longer than most first-time founders plan for. The work splits into building the list, running outreach, taking meetings, and closing, and each stage can stretch. Start before you need the money, not when the runway is short.

Data: RaiseHunt investor dataset · Snapshot 26 September 2026 · How this data is built · Report a correction or request removal